PrEP: latest news

PrEP resources

  • Pre-exposure prophylaxis (PrEP)

    Pre-exposure prophylaxis (PrEP) is a form of HIV prevention that uses medication to protect HIV-negative people from acquiring HIV. It means people take anti-HIV drugs when they...

    From: Factsheets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • 1 In 4 Gay Men Should Take The Pill That Prevents HIV, CDC Says

    Truvada prevents HIV, but only 21,000 people are taking the once-a-day pill. On Tuesday, federal health experts said that if we really want to stop the AIDS epidemic, that number should be more than 1.2 million.

    25 November 2015 | BuzzFeed News
  • CDC on HIV prevention pill: How to tell whether you should be taking the medication

    The Centers for Disease Control and Prevention is making a big push to get more people at "substantial" risk of getting HIV to start on a daily pill that has been shown to dramatically reduce their risk of infection.

    25 November 2015 | Washington Post
  • France Leads the Way with PrEP Approval 5 years after iPrEX

    PrEP has arrived… in France! Marisol Touraine, the French Health Minister announced today that the drug Truvada (manufactured by Gilead) is soon to be approved for the prevention of HIV infection (Pre-Exposure Prophylaxis). Meanwhile, in the UK, with 500 new infections every month, the decision to provide PrEP is somewhere lost in limbo.

    24 November 2015 | Incidence 0
  • 12 months of liquid formula HIV drugs protect breastfeeding babies against HIV

    A study from four countries in Africa, published in The Lancet, shows that providing babies with up to 12 months of liquid formula HIV drugs, while breastfeeding with their HIV-positive mothers, is highly effective at protecting them from infection, including in the 6–12 month period after birth which has not been analysed in previous research.

    23 November 2015 |
  • Very Low HIV Rate in Study of High-Risk Gays on PrEP

    A major American real-world study of PrEP among high-risk men who have sex with men has seen a very low HIV rate despite a high rate of other STIs.

    16 November 2015 | AIDSMeds
  • How one activist is spearheading PrEP awareness in the United Kingdom

    Greg Owen is the leading PrEP activist in the UK, leading the charge among gay and bisexual men to get the word out about PrEP, the once daily pill to prevent HIV.

    10 November 2015 | HIV Equal
  • Will Nutland: The emergence of the end of HIV

    Will Nutland proposes that instead of the Hollywood style ‘end of AIDS moment’ fantasy, the end of AIDS will be a process with a number of emerging endpoints. In this eye-opening talk, Will introduces PrEP and rectal microbicides and discusses their efficacy and levels of acceptability. He surmises that the end might happen without us even noticing.

    10 November 2015 | TEDx Talks / You Tube
  • HIV-preventive medicine available from December in Kolkata's Sonagachi

    One of Asia’s largest red light districts, Sonagachi, will next month roll out an experimental project for providing HIV-preventive medicine to sex workers in what will be the first such initiative in the country.

    10 November 2015 | The Indian Express
  • PrEP is a game changer in HIV prevention, but why isn’t it available to women?

    Susan Cole believes Pre-Exposure Prophylaxis (PrEP) is an important and effective HIV prevention tool, according to the trial results. So why is the NHS hesitating to offer it to women?

    10 November 2015 | The F Word
  • HIV prevention: New look at PrEP study points to efficacy for transgender women

    In a new look at the groundbreaking iPrEx trial for people at high risk of HIV infection, researchers have identified strong evidence of efficacy for transgender women when PrEP, a two-drug antiretroviral used to prevent HIV, is used consistently.

    09 November 2015 | Science Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.